Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $744.52 million. The enterprise value is $467.66 million.
Important Dates
The last earnings date was Wednesday, October 30, 2024, after market close.
| Earnings Date | Oct 30, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 372.26 million shares outstanding. The number of shares has increased by 253.41% in one year.
| Current Share Class | 372.26M |
| Shares Outstanding | 372.26M |
| Shares Change (YoY) | +253.41% |
| Shares Change (QoQ) | -0.21% |
| Owned by Insiders (%) | 1.39% |
| Owned by Institutions (%) | 51.64% |
| Float | 237.17M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.59 |
| Forward PS | 4.11 |
| PB Ratio | 1.52 |
| P/TBV Ratio | 2.07 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.00 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.76, with a Debt / Equity ratio of 0.18.
| Current Ratio | 3.76 |
| Quick Ratio | 3.33 |
| Debt / Equity | 0.18 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -26.26 |
Financial Efficiency
Return on equity (ROE) is -37.25% and return on invested capital (ROIC) is -17.47%.
| Return on Equity (ROE) | -37.25% |
| Return on Assets (ROA) | -14.69% |
| Return on Capital (ROIC) | -17.47% |
| Revenue Per Employee | $289,243 |
| Profits Per Employee | -$316,518 |
| Employee Count | 539 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 2.48 |
Taxes
In the past 12 months, LAB has paid $139,000 in taxes.
| Income Tax | 139,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -4.76% in the last 52 weeks. The beta is 1.57, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.57 |
| 52-Week Price Change | -4.76% |
| 50-Day Moving Average | 1.87 |
| 200-Day Moving Average | 2.14 |
| Relative Strength Index (RSI) | 54.24 |
| Average Volume (20 Days) | 1,603,784 |
Short Selling Information
The latest short interest is 13.77 million, so 3.70% of the outstanding shares have been sold short.
| Short Interest | 13.77M |
| Short Previous Month | 14.68M |
| Short % of Shares Out | 3.70% |
| Short % of Float | 5.80% |
| Short Ratio (days to cover) | 5.30 |
Income Statement
In the last 12 months, LAB had revenue of $155.90 million and -$170.60 million in losses. Loss per share was -$0.62.
| Revenue | 155.90M |
| Gross Profit | 75.71M |
| Operating Income | -119.93M |
| Pretax Income | -118.58M |
| Net Income | -170.60M |
| EBITDA | -114.31M |
| EBIT | -119.93M |
| Loss Per Share | -$0.62 |
Full Income StatementBalance Sheet
The company has $366.33 million in cash and $89.47 million in debt, giving a net cash position of $276.86 million or $0.74 per share.
| Cash & Cash Equivalents | 366.33M |
| Total Debt | 89.47M |
| Net Cash | 276.86M |
| Net Cash Per Share | $0.74 |
| Equity (Book Value) | 489.33M |
| Book Value Per Share | 1.31 |
| Working Capital | 332.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$143.46 million and capital expenditures -$5.05 million, giving a free cash flow of -$148.51 million.
| Operating Cash Flow | -143.46M |
| Capital Expenditures | -5.05M |
| Free Cash Flow | -148.51M |
| FCF Per Share | -$0.40 |
Full Cash Flow StatementMargins
Gross margin is 48.57%, with operating and profit margins of -76.92% and -79.91%.
| Gross Margin | 48.57% |
| Operating Margin | -76.92% |
| Pretax Margin | -79.83% |
| Profit Margin | -79.91% |
| EBITDA Margin | -73.32% |
| EBIT Margin | -76.92% |
| FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -253.41% |
| Shareholder Yield | -253.41% |
| Earnings Yield | -22.91% |
| FCF Yield | -19.95% |
Analyst Forecast
The average price target for LAB is $2.88, which is 44.00% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $2.88 |
| Price Target Difference | 44.00% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 24.47% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of -0.21 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.21 |
| Piotroski F-Score | 4 |